United Therapeutics: Promising Breakthrough in Pediatric Osteosarcoma with OST-HER2 Immunotherapy

Innovative Breakthrough in Pediatric Osteosarcoma Treatment

OS Therapies, Inc. announces significant advancements in its Phase 2b clinical trial for OST-HER2, an immunotherapy targeting HER2 to prevent recurrent lung metastatic osteosarcoma in pediatric patients. The trial, registered under NCT04974008, yields promising results with a notable increase in the primary endpoint of 12-month event-free survival (EFS). A remarkable 33% of patients treated with OST-HER2 remain event-free at the 12-month mark, compared to only 20% in a historical control group, achieving statistical significance (p = 0.0158). These findings highlight the potential of OST-HER2 to fill a critical therapeutic gap for a population that currently lacks approved treatment options.

The interim analysis of the trial also reveals a favorable trend in overall survival (OS) rates, with 91% of OST-HER2 patients alive at one year, in contrast to 80% among historical controls (p = 0.0700). This data reflects the therapy's promising safety profile, as all patients who met the primary endpoint of 12-month EFS are still living at the time of reporting. Dr. Robert Petit, Chief Medical & Scientific Officer of OS Therapies, emphasizes the importance of these results, stating that OST-HER2 addresses a significant unmet medical need in the challenging landscape of pediatric oncology.

The company is now strategically preparing to engage with the U.S. Food and Drug Administration (FDA) regarding an accelerated approval pathway for OST-HER2, aligning its approach with recent updates in FDA guidance. With a clinical trial involving 39 evaluable patients aged 12 to 39, treated at 21 centers over 52 weeks with dosing every three weeks, OS Therapies positions itself at the forefront of innovation in the treatment of osteosarcoma. The positive data from this trial reinforces OST-HER2's potential as a groundbreaking therapeutic option for patients grappling with this difficult-to-treat condition.

In related developments, OS Therapies continues to focus on expanding its clinical pipeline, aiming to address various unmet medical needs within oncology. The promising results from the OST-HER2 trial not only enhance the company's credibility but also signal a new era in pediatric cancer treatment, where innovative therapies may offer hope to patients and families facing dire prognoses. As the company prepares for discussions with regulatory bodies, the industry closely watches its trajectory and the potential impact of OST-HER2 on pediatric oncology.